Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001:(4):CD000937.
doi: 10.1002/14651858.CD000937.

Magnesium supplementation in pregnancy

M Makrides  1 , C A Crowther
Affiliations

Magnesium supplementation in pregnancy

M Makrides et al. Cochrane Database Syst Rev. 2001.

Update in

  • Magnesium supplementation in pregnancy.
    Makrides M, Crosby DD, Bain E, Crowther CA. Makrides M, et al. Cochrane Database Syst Rev. 2014 Apr 3;2014(4):CD000937. doi: 10.1002/14651858.CD000937.pub2. Cochrane Database Syst Rev. 2014. PMID: 24696187 Free PMC article.

Abstract

Background: Many women, especially those from disadvantaged backgrounds, have intakes of magnesium below recommended levels. Magnesium supplementation during pregnancy may be able to reduce fetal growth retardation and pre-eclampsia, and increase birth weight.

Objectives: The objective of this review was to assess the effects of magnesium supplementation during pregnancy on maternal, neonatal and paediatric outcomes.

Search strategy: We searched the Cochrane Cochrane Controlled Trials Register. The date of the last search was June 2001.

Selection criteria: Randomised and quasi-randomised trials of dietary magnesium supplementation during pregnancy.

Data collection and analysis: Suitability for inclusion and methodological quality were separately assessed by each reviewer. Data were independently extracted by the two reviewers.

Main results: Seven trials involving 2689 women were included. Six of these trials randomly allocated women to either an oral magnesium supplement or a control group, whist the largest trial with 985 women had a cluster design where randomisation was according to study centre. The analysis was conducted with and without the cluster trial. In the analysis of all trials, oral magnesium treatment from before the 25th week of gestation was associated with a lower frequency of preterm birth, (relative risk (RR) 0.73, 95% confidence interval (CI) 0.57 to 0.94), a lower frequency of low birth weight (RR 0.67, 95% CI 0.46 to 0.96) and fewer small for gestational age infants (RR 0.70, 95% CI 0.53 to 0.93) compared with placebo. In addition, magnesium treated women had less hospitalisations during pregnancy (RR 0.66, 95% CI 0.49 to 0.89) and fewer cases of antepartum haemorrhage (RR 0.38, 95% CI 0.16 to 0.90) than placebo treated women. In the analysis excluding the cluster randomised trial, the effects of magnesium treatment on the frequencies of preterm birth, low birth weight and small for gestational age were not different from placebo. Of the seven trials included in the review, only one was judged to be of high quality. Poor quality trials are likely to have resulted in a bias favouring magnesium supplementation.

Reviewer's conclusions: There is not enough high quality evidence to show that dietary magnesium supplementation during pregnancy is beneficial.

PubMed Disclaimer

Update of

Publication types

LinkOut - more resources